HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of Pendrin by a small molecule reduces Lipopolysaccharide-induced acute Lung Injury.

Abstract
Rationale: Pendrin is encoded by SLC26A4 and its mutation leads to congenital hearing loss. Additionally, pendrin is up-regulated in inflammatory airway diseases such as chronic obstructive pulmonary disease, allergic rhinitis, and asthma. In this study, the effects of a novel pendrin inhibitor, YS-01, were investigated in an LPS-induced acute lung injury (ALI) mice model, and the mechanism underlying the effect of YS-01 was examined. Methods: Lipopolysaccharide (LPS, 10 mg/kg) was intranasally instilled in wild type (WT) and pendrin-null mice. YS-01 (10 mg/kg) was administered intra-peritoneally before or after LPS inhalation. Lung injury parameters were assessed in the lung tissue and bronchoalveolar lavage fluid (BALF). Pendrin levels in the BALF of 41 patients with acute respiratory distress syndrome (ARDS) due to pneumonia and 25 control (solitary pulmonary nodule) patients were also measured. Results: LPS instillation induced lung injury in WT mice but not in pendrin-null mice. Pendrin expression was increased by LPS stimulation both in vitro and in vivo. YS-01 treatment dramatically attenuated lung injury and reduced BALF cell counts and protein concentration after LPS instillation in WT mice. Proinflammatory cytokines and NF-κB activation were suppressed by YS-01 treatment in LPS-induced ALI mice. In BALF of patients whose ARDS was caused by pneumonia, pendrin expression was up-regulated compared to that in controls (mean, 24.86 vs. 6.83 ng/mL, P < 0.001). Conclusions: A novel pendrin inhibitor, YS-01, suppressed lung injury in LPS-induced ALI mice and our data provide a new strategy for the treatment of inflammatory airway diseases including sepsis-induced ALI.
AuthorsEun Hye Lee, Mi Hwa Shin, Mia Gi, Jinhong Park, Doona Song, Young-Min Hyun, Ji-Hwan Ryu, Je Kyung Seong, Yoon Jeon, Gyoonhee Han, Wan Namkung, Moo Suk Park, Jae Young Choi
JournalTheranostics (Theranostics) Vol. 10 Issue 22 Pg. 9913-9922 ( 2020) ISSN: 1838-7640 [Electronic] Australia
PMID32929324 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The author(s).
Chemical References
  • Cytokines
  • Lipopolysaccharides
  • NF-kappa B
  • Oxazoles
  • Slc26a4 protein, mouse
  • Small Molecule Libraries
  • Sulfate Transporters
  • YS-01
Topics
  • Acute Lung Injury (chemically induced, drug therapy, metabolism)
  • Aged
  • Animals
  • Bronchoalveolar Lavage Fluid
  • Cytokines (metabolism)
  • Disease Models, Animal
  • Female
  • Gene Expression Regulation (drug effects)
  • Humans
  • Inflammation (drug therapy, metabolism)
  • Lipopolysaccharides (pharmacology)
  • Lung (drug effects, metabolism)
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Middle Aged
  • NF-kappa B (metabolism)
  • Oxazoles (pharmacology)
  • Pneumonia (drug therapy, metabolism)
  • Respiratory Distress Syndrome (chemically induced, drug therapy, metabolism)
  • Signal Transduction (drug effects)
  • Small Molecule Libraries (pharmacology)
  • Sulfate Transporters (antagonists & inhibitors)
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: